CD4 and neoplasm: Using peptide screening methodology, nine HER3 peptides with capability to binding MHC-II were identified, and the HER3 peptide-pulsed DC vaccine generated specific CD4+ Th1 antitumor immune response impeding tumor growth in HER3-experssing mouse tumor models.